Ir para o conteúdo principal

Biomea Fusion (NASDAQ: BMEA) — Perfil da empresa, notícias e dados financeiros

Logo de Biomea Fusion
BMEA Biomea Fusion
Biomea Fusion primary media
Perfil da empresa

Biomea Fusion

Biomea Fusion (NASDAQ:BMEA) is a dynamic biotech company focused on discovering and developing innovative treatments for patients battling cancer and other grave diseases. Their projects primarily involve the investigation of novel covalent small molecules that can potentially offer transformative outcomes in the field of oncology and beyond. With a commitment to advancing science and improving lives, Biomea Fusion's objectives encompass the successful progression of their drug candidates through clinical trials, aiming for breakthrough therapies that can meaningfully improve patient outcomes. At the heart of their operations is a dedication to leveraging cutting-edge science to address unmet medical needs, identifying and targeting critical pathways in disease mechanisms.

Resumo

Public USParticipação acionária
2017Ano de fundação
102Funcionários
California, United StatesSede
Carregando mapa...
Presença global

Operações

Todos os locais
United States

Produtos e/ou serviços de Biomea Fusion

  • Covalent menin inhibition technology, targeting a range of cancers.
  • BMF-219, an oral small molecule, focused on difficult-to-treat cancers.
  • Preclinical programs studying the potential in a variety of solid and hematologic malignancies.
  • Collaborations aimed at advancing precision oncology treatments.
  • Research into the molecular drivers of disease to inform future therapies.
  • Development of biomarker-driven approaches to match patients with the most effective treatments.

equipe executiva do Biomea Fusion

  • Michael J. M. HitchcockInterim CEO & Director
  • Ramses M. ErdtmannCo-Founder, President, COO & Director
  • Heow TanChief Technical & Quality Officer
  • Caroline Perez- DupontSenior Vice President of Legal
  • Thorsten KirschbergExecutive Vice President of Research
  • Stephan MorrisChief Development Officer
  • Ravi UpasaniExecutive Vice President of Intellectual Property

Principais indicadores financeiros

Resultados divulgados pela Biomea Fusion, em USD.

Cap. de mercado
46,9 mi
Receita (TTM)
0
P/L
—
LPA (diluído, TTM)
-0.3
Dividend yield
—
Margem de lucro
0.0%
Receita e lucro anuais da Biomea Fusion
Fim do ano fiscalReceitaResultado operacionalLucro líquido
0-81,3 mi-61,8 mi
0-144,1 mi-138,4 mi
0-126,1 mi-117,3 mi
0-83,6 mi-80 mi